France limits who can prescribe XURTA and requires heart monitoring
France's health and public accounts ministers have set new prescribing conditions for XURTA, an amphetamine-class medicine, on the public reimbursement list. The order follows a transparency commission opinion from 8 October 2025 citing heart, growth and brain-related risks. Only specialists in neurology, psychiatry or paediatrics may make the first yearly prescription and yearly renewals, with heart monitoring required.
This summary was generated by AI; the official source prevails.
What does it mean?
Only certain specialist doctors can start or renew the yearly prescription for XURTA, which is covered by public health insurance. Patients on it also need regular heart checks, including a cardiac ultrasound, to watch for possible side effects.
Who is affected?
Patients taking XURTA covered by French public health insurance, and the doctors who prescribe it.
What changes?
Before this order, XURTA was reimbursed without these prescriber limits and monitoring conditions; now only specialists may start or renew the yearly prescription and regular heart checks are required.